ࡱ> ;bjbj 0ngng9 \\\\\ppp8t|p9E`"##b#$>&,(CCCCCCC$HJC\($$((C\\#b#4D@-@-@-(F\#\b#C@-(C@-@-j=^@#TP (v?$C E09E?WKT)WKH^@^@FWK\A@-(((CCb+(((9E((((WK((((((((( X ": Therapeutic Use Exemption (TUE) Please complete all sections in capital letters or typing (English only) and transmit the form to the FIS Anti-Doping Department via email to  HYPERLINK "mailto:antidoping@fisski.com" antidoping@fisski.com It is recommended to submit your documents via password-secure email. Alternatively, please request at  HYPERLINK "mailto:antidoping@fisski.com" antidoping@fisski.com the FIS TUE secured upload link. Athlete to complete sections 1, 2, 3 and 7; Physician to complete sections 4, 5 and 6 Illegible or incomplete applications will be returned and will need to be re-submitted in legible and complete form. 1. Athlete Information  FORMCHECKBOX  I am included in the FIS Registered Testing Pool (International-Level Athlete)  FORMCHECKBOX  I am competing at FIS World Cups and/or FIS World Championships (International-Level Athlete) Please note: If you do not meet one of the above criteria, you need to submit your TUE application form to your NADO. If your NADO informs you that you do not meet their respective criteria to review the application, then you have the possibility to apply for a retroactive TUE in case of an adverse analytical finding. Last name FORMTEXT      First name/s FORMTEXT      Genderfemale  FORMCHECKBOX  male  FORMCHECKBOX Date of birth FORMTEXT      Address FORMTEXT      City / Postal code FORMTEXT      Country FORMTEXT      Telephone FORMTEXT      Email FORMTEXT      Sport / discipline FORMTEXT      International Org.International Ski Federation, FISNational Federation FORMTEXT       Next competition date FORMTEXT       2. Previous Applications Have you submitted any previous TUE application(s) to any ADO for the same condition?  FORMCHECKBOX  yes /  FORMCHECKBOX  no For which substance(s) or method(s)?  FORMTEXT       To whom?  FORMCHECKBOX  FIS /  FORMCHECKBOX  other, please specify:  FORMTEXT       When?  FORMTEXT       Decision:  FORMCHECKBOX  Approved /  FORMCHECKBOX  Not Approved 3. Retroactive Applications Is this a retroactive application?  FORMCHECKBOX  yes /  FORMCHECKBOX  no If yes, on what date was the treatment started:  FORMTEXT       Do any of the following exceptions apply: (Article 4.1 of the ISTUE):  FORMCHECKBOX  4.1 (a) You required emergency or urgent treatment of a medical condition  FORMCHECKBOX  4.1 (b) There was insufficient time, opportunity or other exceptional circumstances that prevented you from submitting the TUE application, or having it evaluated, before getting tested.  FORMCHECKBOX  4.1 (c) You were not permitted or required to apply in advance for a TUE as per the FIS anti-doping rules.  FORMCHECKBOX  4.1 (d) You are a lower-level athlete who is not under the jurisdiction of an International Federation or National Anti-Doping Organization and were tested.  FORMCHECKBOX  4.1 (e) You tested positive after using a substance Out-of-Competition that was only prohibited In-Competition, e.g., S9 glucocorticoids (See  HYPERLINK "https://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf" Prohibited List) Please explain (if necessary, attach further documents)  FORMTEXT        FORMCHECKBOX  Other Retroactive Applications (ISTUE Article 4.3) In rare and exceptional circumstances notwithstanding any other provision in the ISTUE, an Athlete may apply for and be granted retroactive approval for their TUE if, considering the purpose of the Code, it would be manifestly unfair not to grant a retroactive TUE. In order to apply under Article 4.3, please include a full reasoning and attach all necessary supporting documentation.  FORMTEXT       Physician to complete sections 4, 5 and 6. 4. Medical Information (please attach relevant medical documentation) Diagnosis (please use the WHO ICD 11 classification if possible) FORMTEXT        5. Medication Details Prohibited Substance/s: Generic name(s)DoseRoute of AdministrationFrequencyDuration of treatment1.  FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT      2.  FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT      3.  FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       FORMTEXT       Evidence confirming the diagnosis must be attached and forwarded with this application. The medical information must include a comprehensive medical history and the results of all relevant examinations, laboratory investigations and imaging studies. Copies of the original reports or letters should be included when possible. In addition, a short summary that includes the diagnosis, key elements of the clinical exams, medical tests and the treatment plan would be helpful. If a permitted medication can be used to treat the medical condition, please provide justification for the therapeutic use exemption for the prohibited medication. WADA maintains a series of TUE Checklists to assist athletes and physicians in the preparation of complete and thorough TUE applications. These can be accessed by entering the search term Checklist on the WADA website:  HYPERLINK "https://www.wada-ama.org" https://www.wada-ama.org. 6. Medical Practitioners Declaration I certify that the information at sections 4 and 5 above is accurate. I acknowledge and agree that my personal information may be used by Anti-Doping Organization(s) (ADO) to contact me regarding this TUE application, to verify the professional assessment in connection with the TUE process, or in connection with Anti-Doping Rule Violation investigations or proceedings. I further acknowledge and agree that my personal information will be uploaded to the Anti-Doping Administration and Management System (ADAMS) for these purposes (see the  HYPERLINK "https://adams-help.wada-ama.org/hc/en-us/articles/360012071820-ADAMS-Privacy-Policy" \l "h_01121492-b374-476b-b44a-948d88fa3544" ADAMS Privacy Policy for more details). Name FORMTEXT      Medical speciality FORMTEXT      License numberLicense bodyAddress FORMTEXT      City/Postal codeCountryTelephone (incl international code) FORMTEXT      Email FORMTEXT      Date and Signature of the Medical Practitioner  7. Athlete s Declaration I, __________________________________, certify that the information set out at sections 1, 2, 3 and 7 is accurate and complete. I authorize my physician(s) to release the medical information and records that they deem necessary to evaluate the merits of my TUE application to the following recipients: the Anti-Doping Organization(s) (ADO) responsible for making a decision to grant, reject, or recognize my TUE; the World Anti-Doping Agency (WADA), who is responsible for ensuring determinations made by ADOs respect the ISTUE; the physicians who are members of relevant ADO(s) and WADA TUE Committees (TUECs) who may need to review my application in accordance with the World Anti-Doping Code and International Standards; and, if needed to assess my application, other independent medical, scientific or legal experts. I further authorize FIS to release my complete TUE application, including supporting medical information and records, to other ADO(s) and WADA for the reasons described above, and I understand that these recipients may also need to provide my complete application to their TUEC members and relevant experts to assess my application. I have read and understood the TUE Privacy Notice (below) explaining how my personal information will be processed in connection with my TUE application, and I accept its terms. Date FORMTEXT      Athletes signature(If the Athlete is a Minor or has an impairment preventing them from signing this form, a parent or guardian shall sign on behalf of the Athlete):Date FORMTEXT      Parents/Guardians signature  TUE Privacy Notice This Notice describes the personal information processing that will occur in connection with your submission of a TUE Application. TYPES OF PERSONAL INFORMATION (PI) The information provided by you or your physician(s) on the TUE Application Form (including your name, date of birth, contact details, sport and discipline, the diagnosis, medication, and treatment relevant to your application); Supporting medical information and records provided by you or your physician(s); and Assessments and decisions on your TUE application by ADOs (including WADA) and their TUE Committees and other TUE experts, including communications with you and your physician(s), relevant ADOs or support personnel regarding your application. PURPOSES & USE Your PI will be used in order to process and evaluate the merits of your TUE application in accordance with the International Standard for Therapeutic Use Exemptions In some instances, it could be used for other purposes in accordance with the World Anti-Doping Code (Code), the International Standards, and the anti-doping rules of ADOs with authority to test you. This includes: Results management, in the event of an adverse or atypical finding based on your sample(s) or the Athlete Biological Passport; and In rare cases, investigations, or related procedures in the context of a suspected Anti-Doping Rule Violation (ADRV). TYPES OF RECIPIENTS Your PI, including your medical or health information and records, may be shared with the following: ADO(s) responsible for making a decision to grant, reject, or recognize your TUE, as well as their delegated third parties (if any). The decision to grant or deny your TUE application will also be made available to ADOs with testing authority and/or results management authority over you; WADA authorized staff; Members of the TUE Committees (TUECs) of each relevant ADO and WADA; and Other independent medical, scientific or legal experts, if needed. Note that due to the sensitivity of TUE information, only a limited number of ADO and WADA staff will receive access to your application. ADOs (including WADA) must handle your PI in accordance with the International Standard for the Protection of Privacy and Personal Information (ISPPPI). You may also consult the ADO to which you submit your TUE application to obtain more details about the processing of your PI. Your PI will also be uploaded to ADAMS by the ADO who receives your application so that it may be accessed by other ADOs and WADA as necessary for the purposes described above. ADAMS is hosted in Canada and is operated and managed by WADA. For details about ADAMS, and how WADA will process your PI, consult the ADAMS Privacy Policy ( HYPERLINK "https://adams-help.wada-ama.org/hc/en-us/articles/360012071820-ADAMS-Privacy-Policy" \l "h_01121492-b374-476b-b44a-948d88fa3544" ADAMS Privacy Policy). FAIR & LAWFUL PROCESSING When yo !"#BU챜xfQ81jhVh?CJOJQJU^JaJmH sH (hVhCJOJQJ^JaJmH sH "h7?CJOJQJ^JaJmH sH "hVCJOJQJ^JaJmH sH "hS CJOJQJ^JaJmH sH (hVh:CJOJQJ^JaJmH sH (h:h:CJOJQJ^JaJmH sH %h:5CJ OJQJ^JaJ mH sH %hn t5CJ OJQJ^JaJ mH sH %hf&5CJ OJQJ^JaJ mH sH !"# 6 + ~ T7x]T^7`gd(3Tx]T^gd[ T]T^gdIY $ h]h^a$gd^n$Tx]T^a$gd: Tx]Tgd$T]T^a$gd?n      # % 0 > g h { | } ϶xgggYgggDggggggggg)jh^nh^nCJOJQJU^JaJh^nCJOJQJ^JaJ h^nh^nCJOJQJ^JaJ"hH=CJOJQJ^JaJmH sH (hVh:CJOJQJ^JaJmH sH ,hVh?0JCJOJQJ^JaJmH sH 1jhVh?CJOJQJU^JaJmH sH 7jhVh?CJOJQJU^JaJmH sH (hVh?CJOJQJ^JaJmH sH     + , - / 4 5 6 ƸƦzzzzzzhS(hVh"/CJOJQJ^JaJmH sH "h"/CJOJQJ^JaJmH sH +h^nhS >*CJOJQJ^JaJmH sH +h^nh"/>*CJOJQJ^JaJmH sH "h^nCJOJQJ^JaJmH sH h^nCJOJQJ^JaJ h^nh^nCJOJQJ^JaJ$h^nh^n0JCJOJQJ^JaJ)jh^nh^nCJOJQJU^JaJ ͻwgR@RRR+(h(3h(3CJOJQJ^JaJmH sH "h(3CJOJQJ^JaJmH sH (h(3h[CJOJQJ^JaJmH sH h[OJQJ^JaJmH sH 3jh6h,]OJQJU^JaJmH sH $h6h[OJQJ^JaJmH sH -jh6h[OJQJU^JaJmH sH #hIYh:5OJQJ^JmH sH  h:h:OJQJ^JmH sH #h:hIY5OJQJ^JmH sH hIY5OJQJ^JmH sH  * + , : ; < ? @ | ~ ԻԟxcP<('hVhV5CJOJQJ^JmH sH 'hVhV6CJOJQJ^JmH sH %h[6CJOJQJ^JaJmH sH (h(3h(3CJOJQJ^JaJmH sH "h(3CJOJQJ^JaJmH sH (h(3hH=CJOJQJ^JaJmH sH 7jeh(3h[CJOJQJU^JaJmH sH 1jh(3h[CJOJQJU^JaJmH sH (h(3h[CJOJQJ^JaJmH sH +h(3h(36CJOJQJ^JaJmH sH ~ T$If]T^gd!Ll 0T$If]Tgdf&l 0T]TgdIYTx]T^gdVT7x]T^7gd(3 ˶sWAAAAA+jh,]CJOJQJU^JaJmH sH 7jhVhCJOJQJU^JaJmH sH (hVh6CJOJQJ^JaJmH sH 1jhVh6CJOJQJU^JaJmH sH (hVh:CJOJQJ^JaJmH sH (hVh pCJOJQJ^JaJmH sH #h:h:5OJQJ^JmH sH hVCJOJQJ^JmH sH $hVhVCJOJQJ^JmH sH  .02468:<>@BP^`|~Ŭ{^^^^^ŬB7jhVh!LCJOJQJU^JaJmH sH 8jhVh6CJOJQJU^JaJmHnHsH u7jhVhCJOJQJU^JaJmH sH (hVh6CJOJQJ^JaJmH sH 1jhVh6CJOJQJU^JaJmH sH (hVh:CJOJQJ^JaJmH sH (hVh pCJOJQJ^JaJmH sH  hVh:CJOJQJ^JaJ @hMT$If]T^gd:l 0T$If]Tgdf&l 0kdc$$Ifl0 % t0$644 laytV@BPhMT$If]T^gd:l T$If]Tgdf&l kdn$$Ifl0 % t0$644 laytV   ~bEEEEE~8jhVh6CJOJQJU^JaJmHnHsH u7jhVhCJOJQJU^JaJmH sH  hVh:CJOJQJ^JaJ7jhVhCJOJQJU^JaJmH sH (hVh6CJOJQJ^JaJmH sH 1jhVh6CJOJQJU^JaJmH sH (hVh:CJOJQJ^JaJmH sH "hS CJOJQJ^JaJmH sH hMT$If]T^gd:l T$If]Tgdf&l kd$$Ifl0 % t0$644 laytV 2hMT$If]T^gd:l T$If]Tgdf&l kd$$$Ifl0 % t0$644 laytV "$&(*,.024Z\prtvxz|~ʭʘrVʭʘr7jhVhCJOJQJU^JaJmH sH (hVh6CJOJQJ^JaJmH sH  hVh:CJOJQJ^JaJ(hVh:CJOJQJ^JaJmH sH 8jhVh6CJOJQJU^JaJmHnHsH u1jhVh6CJOJQJU^JaJmH sH 7jhVhCJOJQJU^JaJmH sH 24ZhMT$If]T^gd:l T$If]Tgdf&l kd/$$Ifl0 % t0$644 laytVhMT$If]T^gd:l T$If]Tgdf&l kd:$$Ifl0 % t0$644 laytVʭʘrVʭʘA(hVhICJOJQJ^JaJmH sH 7j hVhCJOJQJU^JaJmH sH (hVh6CJOJQJ^JaJmH sH  hVh:CJOJQJ^JaJ(hVh:CJOJQJ^JaJmH sH 8jhVh6CJOJQJU^JaJmHnHsH u1jhVh6CJOJQJU^JaJmH sH 7jhVhCJOJQJU^JaJmH sH hMT$If]T^gd:l T$If]Tgdf&l kdE $$Ifl0 % t0$644 laytV0hMT$If]T^gd:l T$If]Tgdf&l kdP $$Ifl0 % t0$644 laytV  "$&(*,.02XZnprtvxz|~ҽ҄sҽW҄ss7j hVhCJOJQJU^JaJmH sH  hVh:CJOJQJ^JaJ8jhVh6CJOJQJU^JaJmHnHsH u7j hVhCJOJQJU^JaJmH sH (hVh6CJOJQJ^JaJmH sH 1jhVh6CJOJQJU^JaJmH sH (hVh:CJOJQJ^JaJmH sH 02XhMT$If]T^gd:l T$If]Tgdf&l kd[ $$Ifl0 % t0$644 laytVhMT$If]T^gd:l T$If]Tgdf&l kdf $$Ifl0 % t0$644 laytV>hMT$If]T^gd:l T$If]Tgdf&l kd $$Ifl0 % t0$644 laytV,.02468:<>@BnpҙxcJc1jhi"kh *CJOJQJU^JaJmH sH (hi"kh *CJOJQJ^JaJmH sH h *CJOJQJ^JmH sH  hVhCJOJQJ^JaJ8jhVhCJOJQJU^JaJmHnHsH u7j hVhCJOJQJU^JaJmH sH 1jhVhCJOJQJU^JaJmH sH (hVhCJOJQJ^JaJmH sH >@BnpYYT$If]Tgdi"kl Tx]T^gd *kd $$Ifl0 % t0$644 laytVʵvvgUgg@(h *hS CJOJQJ^JaJmH sH #h:hS 5OJQJ^JmH sH hS 5OJQJ^JmH sH h5OJQJ^JmH sH h^5OJQJ^JmH sH h:OJQJ^JmH sH $hi"kh *CJOJQJ^JmH sH (hi"kh *CJOJQJ^JaJmH sH 1jhi"kh *CJOJQJU^JaJmH sH 7jhi"kh *CJOJQJU^JaJmH sH viiiiXKK T]T^gdS  T]T^gdS T]T^gd:kd $$IfF0 % t0$644 lapyti"k4P~(.46JLNPRTVXZ\^lpr٤وl7jh *hS CJOJQJU^JaJmH sH 7j>h *hS CJOJQJU^JaJmH sH 7jh *hS CJOJQJU^JaJmH sH 1jh *hS CJOJQJU^JaJmH sH (h *hS CJOJQJ^JaJmH sH "hS CJOJQJ^JaJmH sH (\^ TV"$Z\T]T^gd4Tl  T]T^gd4T T]T^gdS  ,.BDFHJLNPʵʵʵʵ}kkʵO7jh *hS CJOJQJU^JaJmH sH "hS CJOJQJ^JaJmH sH 7jFh *hS CJOJQJU^JaJmH sH 7jh *hS CJOJQJU^JaJmH sH (h *hS CJOJQJ^JaJmH sH 1jh *hS CJOJQJU^JaJmH sH 7j2h *hS CJOJQJU^JaJmH sH PRTVhjl"$pԿ濣Կ濇xfxXC(hRGh4TCJOJQJ^JaJmH sH h4TOJQJ^JmH sH #h:h4T5OJQJ^JmH sH h4T5OJQJ^JmH sH 7jh *hS CJOJQJU^JaJmH sH 7jh *hS CJOJQJU^JaJmH sH (h *hS CJOJQJ^JaJmH sH "hS CJOJQJ^JaJmH sH 1jh *hS CJOJQJU^JaJmH sH pr .24HJLѵљчsdJs2jBh6h4T5OJQJU^JmH sH h4T5OJQJ^JmH sH &jh4T5OJQJU^JmH sH "h4TCJOJQJ^JaJmH sH 7jhRGh4TCJOJQJU^JaJmH sH 7j.hRGh4TCJOJQJU^JaJmH sH (hRGh4TCJOJQJ^JaJmH sH 1jhRGh4TCJOJQJU^JaJmH sH LNPRTVXZ\  ųi]]]A7jBhVh4TCJOJQJU^JaJmH sH h4TCJOJQJ^J7jhVh4TCJOJQJU^JaJmH sH (hVh4TCJOJQJ^JaJmH sH 1jhVh4TCJOJQJU^JaJmH sH "h4TCJOJQJ^JaJmH sH h4T5OJQJ^JmH sH &jh4T5OJQJU^JmH sH -jh4T5OJQJU^JmHnHsH uO*+,-5BɴuuɴYɴ7jVhVh4TCJOJQJU^JaJmH sH h4TB*CJOJQJ^Jph%h4Th4TB*CJOJQJ^Jph7jhVh4TCJOJQJU^JaJmH sH (hVh4TCJOJQJ^JaJmH sH 1jhVh4TCJOJQJU^JaJmH sH h4TCJOJQJ^J"h4TCJOJQJ^JaJmH sH Zjklʸn_h4T5OJQJ^JmH sH &jh4T5OJQJU^JmH sH h4TCJOJQJ^JmH sH h4T0JCJOJQJ^Jh4Tjh4TUh4TCJOJQJ^J"h4TCJOJQJ^JaJmH sH 1jhVh4TCJOJQJU^JaJmH sH 7jhVh4TCJOJQJU^JaJmH sH > @ $T]T^a$gd7 T]T^gd: T]T^gdS d^gd4T T]T^gd4T $1$`gd4T   0246>һҩ{_GG2(h4T5CJOJQJ\^JaJmH sH .h4Th4T5CJOJQJ\^JaJmH sH 7jhVh4TCJOJQJU^JaJmH sH (hVh4TCJOJQJ^JaJmH sH 1jhVh4TCJOJQJU^JaJmH sH "h4TCJOJQJ^JaJmH sH -jh4T5OJQJU^JmHnHsH u&jh4T5OJQJU^JmH sH 2jjh6h4T5OJQJU^JmH sH ߰s\\\\\G(h *hS CJOJQJ^JaJmH sH -jh4T5OJQJU^JmHnHsH u2jjh6h4T5OJQJU^JmH sH &jh4T5OJQJU^JmH sH h4T5OJQJ^JmH sH "h4TCJOJQJ^JaJmH sH h4TCJOJQJ\^Jh4TCJOJQJ^JmH sH h4TCJOJQJ^J(h4T5CJOJQJ\^JaJmH sH  < > @ B d l !!R!T!V!j!᳡zzzhzTEh65OJQJ^JmH sH &jh65OJQJU^JmH sH "h*_CJOJQJ^JaJmH sH "h7CJOJQJ^JaJmH sH (h}h:CJOJQJ^JaJmH sH #h:h}5OJQJ^JmH sH h:5OJQJ^JmH sH #h:h:5OJQJ^JmH sH h75OJQJ\^Jh75OJQJ^JmH sH hS 5OJQJ^JmH sH @ !T!|!~!!!!!T$If]T^gd*_l T$If]Tgdf&l T$If]T^gd:l  T]T^gd: j!l!n!p!r!t!v!x!z!|!~!!!!!!!!!!һҬtgUF77hF5OJQJ^JmH sH h6CJOJQJ^JaJ#h hI6CJOJQJ^JaJh:h:OJQJ^J'h}h:5CJOJQJ^JmH sH #h:h:5OJQJ^JmH sH #h:hf&5OJQJ^JmH sH h:5OJQJ^JmH sH -jh65OJQJU^JmHnHsH u&jh65OJQJU^JmH sH 2jh6h5OJQJU^JmH sH !!!!!!!!vviii\ T]T^gd: T]T^gd^gdIkdV$$Ifl 0# Z& 7 t0>%644 laytF!!!!"" """""F"H"\""""""Ϲ{{i{{i{\{G(hh6CJOJQJ^JaJmH sH h:h:OJQJ^J"hCJOJQJ^JaJmH sH (hh:CJOJQJ^JaJmH sH +hh:5CJOJQJ^JaJmH sH %h*_5CJOJQJ^JaJmH sH +hhl5CJOJQJ^JaJmH sH #h:hI5OJQJ^JmH sH h5OJQJ^JmH sH h*_5OJQJ^JmH sH !""H"\""T$If]T^gdl T$If]T^gd:l """F/T$If]Tgd:l kd$$Iflr F%  t0$644 layt"""""""""""""""""""""""""""""#ѵ昘g昘K昘7jhhCJOJQJU^JaJmH sH 7j$hhCJOJQJU^JaJmH sH (hh:CJOJQJ^JaJmH sH 8jhh6CJOJQJU^JaJmHnHsH u7jhhCJOJQJU^JaJmH sH (hh6CJOJQJ^JaJmH sH 1jhh6CJOJQJU^JaJmH sH ""#0#X#T$If]T^gd:l ##### ## #"#$#&#(#*#,#.#0#2#F#H#J#L#N#P#R#T#V#X#Z#^#`#b#v#ʵʠʵʠhʵ[ʠh:h:OJQJ^J7jhhCJOJQJU^JaJmH sH 7jhhCJOJQJU^JaJmH sH (hh6CJOJQJ^JaJmH sH (hh:CJOJQJ^JaJmH sH 1jhh6CJOJQJU^JaJmH sH 8jhh6CJOJQJU^JaJmHnHsH uX#Z##F/T$If]Tgd:l kd$$Iflr F%  t0$644 laytv#x#z#|#~##########################ʭʘʃgʭʘʃKʭ7jhhCJOJQJU^JaJmH sH 7j3hhCJOJQJU^JaJmH sH (hh6CJOJQJ^JaJmH sH (hh:CJOJQJ^JaJmH sH 8jhh6CJOJQJU^JaJmHnHsH u1jhh6CJOJQJU^JaJmH sH 7jhhCJOJQJU^JaJmH sH ###$($T$If]T^gd:l #############$$$$$$$ $"$$$&$($*$.$0$2$F$漠惃g惃ZѼh:h:OJQJ^J7j hhCJOJQJU^JaJmH sH 8jhh6CJOJQJU^JaJmHnHsH u7j hhCJOJQJU^JaJmH sH (hh6CJOJQJ^JaJmH sH (hh:CJOJQJ^JaJmH sH 1jhh6CJOJQJU^JaJmH sH ($*$X$F/T$If]Tgd:l kd !$$Iflr F%  t0$644 laytF$H$J$L$N$P$R$T$V$X$Z$n$p$r$t$v$x$z$|$~$$$$$$$$$$$ʭʘʃgʭʘʃKʭ7j"hhCJOJQJU^JaJmH sH 7jB"hhCJOJQJU^JaJmH sH (hh6CJOJQJ^JaJmH sH (hh:CJOJQJ^JaJmH sH 8jhh6CJOJQJU^JaJmHnHsH u1jhh6CJOJQJU^JaJmH sH 7j!hhCJOJQJU^JaJmH sH X$$$$$T$If]T^gd:l $$$$$$$$$$$$$$$$$$$$$$$$$$$漠惃g惃ZG%h:5CJOJQJ^JaJmH sH h:h:OJQJ^J7j#hhCJOJQJU^JaJmH sH 8jhh6CJOJQJU^JaJmHnHsH u7j.#hhCJOJQJU^JaJmH sH (hh6CJOJQJ^JaJmH sH (hh:CJOJQJ^JaJmH sH 1jhh6CJOJQJU^JaJmH sH $$$Y'Z''F9--- d^gd*_ T]T^gd:kd$$$Iflr F%  t0$644 layt$%&w&x&&'X'Y'Z'''''((((()))))))) )!)")#)$)%)&)')()))*)C)𮛈yg#hh:5OJQJ^JmH sH h*_5OJQJ^JmH sH %h*_5CJOJQJ^JaJmH sH %h5CJOJQJ^JaJmH sH #h*_h*_6CJOJQJ^JaJ!h*_0J6CJOJQJ^JaJjh*_U%h*_6CJOJQJ^JaJmH sH h*_h*_6CJOJQJ^JaJ&'') )!)")#)$)%)&)')()))O)P)L,N,X,,T$If]T^gd:l 0T$If]Tgd:l 0 T]T^gd: d^gd*_^gd*_dgd*_C)D)O)P)c){)|))))))))**+e+i+j+m+n+ȳ}}l}}}}UAU}&h*_B*CJOJQJ\^JaJph,h*_h*_B*CJOJQJ\^JaJph h*_h*_CJOJQJ^JaJ#h*_h*_CJOJQJ\^JaJ"h*_CJOJQJ^JaJmH sH "hCJOJQJ^JaJmH sH (h:h:CJOJQJ^JaJmH sH +h:h)5CJOJQJ^JaJmH sH #hh:5OJQJ^JmH sH h5OJQJ^JmH sH n+o+p+++++,",$,&,J,L,N,X,Z,n,p,r,忰p^Bp7j$h6hCJOJQJU^JaJmH sH "h6CJOJQJ^JaJmH sH +jh6CJOJQJU^JaJmH sH (h:h:CJOJQJ^JaJmH sH (h:h*_CJOJQJ^JaJmH sH h:CJOJQJ\^JaJ#h*_h*_CJOJQJ\^JaJ'h*_h*_0JCJOJQJ\^JaJh*_h*_CJaJjh*_h*_CJUaJr,t,v,x,z,|,~,,,,,,,,,,,,,,,,,,,,,,, -лМлnnnYnLnh:h*_OJQJ^J(h:h*_CJOJQJ^JaJmH sH "h*_CJOJQJ^JaJmH sH 7j%h6hCJOJQJU^JaJmH sH "h6CJOJQJ^JaJmH sH h:h:OJQJ^J(h:h:CJOJQJ^JaJmH sH +jh6CJOJQJU^JaJmH sH 2jh6CJOJQJU^JaJmHnHsH u,,,,kPT$If]T^gd:l 0T$If]Tgd:l 0|kdQ%$$Ifl0 % t0$644 la,,,,kPT$If]T^gd:l 0T$If]Tgd:l 0|kdX&$$Ifl0 % t0$644 la,,--kPT$If]T^gd:l 0T$If]Tgd:l 0|kd&$$Ifl0 % t0$644 la ----"-$-8-:-<->-@-B-D-F-H-J-L-l-n-p-r-~---------̶nnnnnaL̶(h:h*_CJOJQJ^JaJmH sH h:h:OJQJ^J2jh6CJOJQJU^JaJmHnHsH u7j (h6hCJOJQJU^JaJmH sH "h6CJOJQJ^JaJmH sH +jh6CJOJQJU^JaJmH sH (h:h:CJOJQJ^JaJmH sH h:h*_OJQJ^J"h*_CJOJQJ^JaJmH sH --"-J-kPT$If]T^gd:l T$If]Tgd:l |kdz'$$Ifl0 % t0$644 laJ-L-n-p-kPT$If]T^gd:l T$If]Tgd:l |kd($$Ifl0 % t0$644 lap-r---kPT$If]T^gd:l T$If]Tgd:l |kd)$$Ifl0 % t0$644 la----kPT$If]T^gd:l T$If]Tgd:l |kd)$$Ifl0 % t0$644 la-------------...... .".$.&.(.*.,...ҼkO7j;+h6hCJOJQJU^JaJmH sH (h:h*_CJOJQJ^JaJmH sH h:h:OJQJ^J(h:h:CJOJQJ^JaJmH sH 2jh6CJOJQJU^JaJmHnHsH u+jh6CJOJQJU^JaJmH sH 7j4*h6hCJOJQJU^JaJmH sH "h6CJOJQJ^JaJmH sH --.,.kPT$If]T^gd:l T$If]Tgd:l |kd*$$Ifl0 % t0$644 la,...V.f....kkkkPT$If]T^gd:l T$If]Tgd:l |kd+$$Ifl0 % t0$644 la..@.T.V.d.f...............ٵٓr`K8$h:h:CJOJQJ^JmH sH (h:h~1CJOJQJ^JaJmH sH "h:CJOJQJ^JaJmH sH #h:h~15OJQJ^JmH sH h~15OJQJ^JmH sH h:h:OJQJ^J(hShSCJOJQJ^JaJmH sH "h:CJOJQJ^JaJmH sH "hRCJOJQJ^JaJmH sH (h:h:CJOJQJ^JaJmH sH "h~1CJOJQJ^JaJmH sH ......//uuhXL@ d^gd*_ d^gdF$T]T^a$gd: T]T^gd*_ T]T^gd~1|kdB,$$Ifl0 % t0$644 la./n////00112222223d333344(5*5:5<5F5H5\5ݺݪݺ}iYh6CJOJQJ^JmH sH 'jh6CJOJQJU^JmH sH $h:h:CJOJQJ^JmH sH 3h*_h*_5B*CJOJQJ\^JmH phsH h*_B*CJOJQJ^Jphh*_CJOJQJ^J-h*_h*_B*CJOJQJ^JmH phsH %h*_h*_B*CJOJQJ^Jphh~1CJOJQJ^JmH sH /233<5F5n5T$If]T^gd:l T$If]Tgd:l  dhX^gdFdgd*_ dh^gdF\5^5`5b5d5f5h5j5l5n5p555556666666666ѹѦzzmzz^QAh6CJOJQJ^JmH sH h:h*_OJQJ^Jh*_h*_CJOJQJ^Jh*_6CJOJQJ^Jh*_CJOJQJ^J$h:h*_CJOJQJ^JmH sH h:h:OJQJ^J$h:h:CJOJQJ^JmH sH .jh6CJOJQJU^JmHnHsH u'jh6CJOJQJU^JmH sH 3j,h6hCJOJQJU^JmH sH n5p555kPT$If]T^gd:l T$If]Tgd:l |kdI-$$Ifl0 % t0$644 la5556kQd$If^gd*_l T$If]Tgd:l |kd-$$Ifl0 % t0$644 la6666kPT$If]T^gd:l T$If]Tgd:l |kdk.$$Ifl0 % t0$644 la666666666666787:7<7>7@7B7f7ѹѦu]H2+h*_h*_5CJOJQJ^JaJmH sH (h[yW5>*CJOJQJ^JaJmH sH .h:h:5>*CJOJQJ^JaJmH sH  h:h:OJQJ^JmH sH $h:h*_CJOJQJ^JmH sH h:h:OJQJ^J$h:h:CJOJQJ^JmH sH .jh6CJOJQJU^JmHnHsH u'jh6CJOJQJU^JmH sH 3j.h6hCJOJQJU^JmH sH 6687:7<7kT9T$If]T^gd:l T$If]Tgd:l T$If]Tgd*_l |kdr/$$Ifl0 % t0$644 la<7>7@7B7h7j788[8@9reee\RJ & Fgd*_ $xa$gd*_^gdF T]T^gd*_$T]T^a$gd:|kd0$$Ifl0 % t0$644 laf7h7j7787888Z8[889?9@9999::::::;;<<<<<<===#=$====>>>>>>? ? ?N?O?P??˾ࡡh*_CJOJPJQJ^J#h*_h*_5CJOJPJQJ^Jh*_CJOJQJ^JaJh*_5CJOJPJQJ^Jh*_5CJOJQJ^J(h*_h*_CJOJPJQJ^JmH sH h*_CJOJQJ^J%h*_5CJOJQJ^JaJmH sH 2@99::<<=$==>> ?O?P?@@BBZ^Zgd?h^hgdFh^hgd*_ h<`hgdF $xxa$gd*_  & Fgd*_ & Fgd*_ h<^hgdF $xa$gd*_  & Fgd*_ & Fgd*_?@s@@@@@AABB@BABBBBBBBBBBBCCCʿʀsbVVh^nCJOJQJ^J!h^n5CJOJQJ^JmH sH h^n5CJOJQJ^JU'h~Vh?5CJOJQJ^JmH sH h~Vh?5CJOJQJ^J#h~Vh?0JCJOJQJ\^J h~Vh?jh~Vh?Uh~Vh?CJOJQJ^Jh?CJOJQJ^Jh?h*_CJOJQJ^Jh*_CJOJQJ^J!BC/0j fhiklnoqr ^gd~V x^gd3W x^gd3W $xa$gd^n ^gd3W $xxa$gd?u sign the Athlete Declaration, you are confirming that you have read and understood this TUE Privacy Notice. Where appropriate and permitted by applicable law, ADOs and other parties mentioned above may also consider that this signature confirms your express consent to the PI processing described in this Notice. Alternatively, ADOs and these other parties may rely upon other grounds recognized in law to process your PI for the purposes described in this Notice, such as the important public interests served by anti-doping, the need to fulfill contractual obligations owed to you, the need to ensure compliance with a legal obligation or a compulsory legal process, or the need to fulfill legitimate interests associated with their activities. RIGHTS You have rights with respect to your PI under the ISPPPI, including the right to a copy of your PI and to have your PI corrected, blocked or deleted in certain circumstances. You may have additional rights under applicable laws, such as the right to lodge a complaint with a data privacy regulator in your country. Where the processing of your PI is based on your consent, you can revoke your consent at any time, including the authorization to your physician to release medical information as described in the Athlete Declaration. To do so, you must notify your ADO and your physician(s) of your decision. If you withdraw your consent or object to the PI processing described in this Notice, your TUE will likely be rejected as ADOs will be unable to properly assess it in accordance with the Code and International Standards. In rare cases, it may also be necessary for ADOs to continue to process your PI to fulfill obligations under the Code and the International Standards, despite your objection to such processing or withdrawal of consent (where applicable). This includes processing for investigations or proceedings related to ADRV, as well as processing to establish, exercise or defend against legal claims involving you, WADA and/or an ADO. SAFEGUARDS All the information contained in a TUE application, including the supporting medical information and records, and any other information related to the evaluation of a TUE request must be handled in accordance with the principles of strict medical confidentiality. Physicians who are members of a TUE Committee and any other experts consulted must be subject to confidentiality agreements. Under the ISPPPI, ADO staff must also sign confidentiality agreements, and ADOs must implement strong privacy and security measures to protect your PI. The ISPPPI requires ADOs to apply higher levels of security to TUE information, because of the sensitivity of this information. You can find information about security in ADAMS by consulting the response to HYPERLINK "https://adams-help.wada-ama.org/hc/en-us/articles/360010175840-How-is-your-information-protected-in-ADAMS-" How is your information protected in ADAMS?in our HYPERLINK "https://adams-help.wada-ama.org/hc/en-us/categories/360001964873-ADAMS-Privacy-and-Security" ADAMS Privacy and Security FAQs. RETENTION Your PI will be retained by ADOs (including WADA) for the retention periods described in Annex A of the ISPPPI. TUE certificates or rejection decisions will be retained for 10 years. TUE application forms and supplementary medical information will be retained for 12 months from the expiry of the TUE. Incomplete TUE applications will be retained for 12 months. CONTACT Consult  HYPERLINK "mailto:antidoping@fisski.com" antidoping@fisski.com for questions or concerns about the processing of your PI. To contact WADA, use  HYPERLINK "mailto:privacy@wada-ama.org" privacy@wada-ama.org     Therapeutic Use Exemption (TUE), version 2021 - PAGE 1- .//0ijIJKvw     %h~Vh^nB*CJOJQJ^Jphh^nCJOJQJ^JmH sH 0h^nh^nB*CJOJQJ^JmHnHphuh^n0JCJOJQJ^Jh^njh^nUh^n5CJOJQJ^Jh^nCJOJQJ^J8%&'NOPde߭×uuia]]]aOah^n0JCJOJQJ^Jh^njh^nUh^nCJOJQJ^Jh~Vh^nCJOJQJ^J%h~Vh^nB*CJOJQJ^Jph*h~Vh^n5B*H*OJQJ\^Jph*h~Vh^n0J6CJOJQJ]^JaJ6h~Vh^n0J6>*B*CJOJQJ]^JaJph?jh~Vh^n0J6>*B*CJOJQJU]^JaJphefghijklmnopqrstu"*+,23456789:;̽ؽl%h^50JCJOJQJ^JmHnHu hAwh\0JCJOJQJ^J)jhAwh\0JCJOJQJU^JhS CJOJQJ^Jh~uCJOJQJ^JhAwh\CJOJQJ^Jh\CJOJQJ^Jh\hEqjhEqU.h:h5>*CJOJQJ^JaJmH sH %rstu789:; ^gd~V !^gdAw^gd'M9.:p:. A!"#$%  DyK antidoping@fisski.comyK :mailto:antidoping@fisski.comDKontrollkstchen2DeKontrollkstchen2tDText1$$If!vh#v#v:V l t0$6,55aytVtDText2$$If!vh#v#v:V l t0$6,55aytVDKontrollkstchen1DeKontrollkstchen2$$If!vh#v#v:V l t0$6,55aytVtDText3$$If!vh#v#v:V l t0$6,55aytVtDText4$$If!vh#v#v:V l t0$6,55aytVtDText5$$If!vh#v#v:V l t0$6,55aytVtDText6$$If!vh#v#v:V l t0$6,55aytVtDText7$$If!vh#v#v:V l t0$6,55aytVtDText8$$If!vh#v#v:V l t0$6,55aytVtDText9$$If!vh#v#v:V l t0$6,55aytV$$If!vh#v#v:V l t0$6,55aytVvDText36$$If!vh#v#v:V l t0$6,55aytVjD$$Ifb!vh#v#v:V F t0$6,55apyti"kDKontrollkstchen1DeKontrollkstchen2jDDKontrollkstchen1DeKontrollkstchen2jDjDDKontrollkstchen1DeKontrollkstchen2DKontrollkstchen1DeKontrollkstchen2vDText10DeKontrollkstchen2DeKontrollkstchen2DeKontrollkstchen2DeKontrollkstchen2DeKontrollkstchen2vDText10DeKontrollkstchen2vDText10vDText10$$If!vh#v #v7:V l t0>%6,5 57aytF$$If!vh#v #v#v#v#v:V l t0$6,5 5555aytvDText11vDText14vDText15vDText20vDText22$$If!vh#v #v#v#v#v:V l t0$6,5 5555aytvDText12vDText16vDText18vDText21vDText23$$If!vh#v #v#v#v#v:V l t0$6,5 5555aytvDText13vDText17vDText19vDText24vDText25$$If!vh#v #v#v#v#v:V l t0$6,5 5555aytvDText27$$If!vh#v#v:V l t0$6,55avDText28$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55avDText29$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55avDText30$$If!vh#v#v:V l t0$6,55avDText32$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55avDText34$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55avDText35$$If!vh#v#v:V l t0$6,55a$$If!vh#v#v:V l t0$6,55a!x2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@66666_HmHnHsHtH<`< NormalCJ_HmH sH tH \\ WsA Heading 1$ d@&5CJmHsHtH`` 1Z Heading 2$<@&$56CJOJPJQJ\]^JaJXX 1Z Heading 6 <@&5CJOJPJQJ\^JaJDA`D Default Paragraph FontZi@Z  Table Normal :V 4 l4a _H(k (No List 4@4 N!Header  !4 @4 N!Footer  !jj N! Table Grid7:V0n"n N!0[Basic Paragraph]d 1$7$8$H$B*OJPJQJmH phsH </1< WsAHeading 1 Char5CJ4U`A4 WsA Hyperlink >*phRBRR WsA Body Text ]OJQJmH sH tHH/aH WsABody Text CharCJOJQJmH sH d/qd 1ZHeading 2 Char056CJOJPJQJ\]^JaJmH sH tH ^/^ 1ZHeading 6 Char*5CJOJPJQJ\^JaJmH sH tH >/> 1Z Header CharCJmH sH tH .)@. Aw Page NumberHH [ Balloon TextCJOJQJ^JaJZ/Z [Balloon Text Char CJOJQJ^JaJmH sH tH >`> 4T0Placeholder TextphZ@Z *_ List Paragraph$^a$m$PJaJmH sH Rv!R ^n0Unresolved MentionB*ph`^\q ZOZ ^n0Body Text 1,b1 $^a$PJaJmH sH PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vj\{cp/IDg6wZ0s=Dĵw %;r,qlEآyDQ"Q,=c8B,!gxMD&铁M./SAe^QשF½|SˌDإbj|E7C<bʼNpr8fnߧFrI.{1fVԅ$21(t}kJV1/ ÚQL×07#]fVIhcMZ6/Hߏ bW`Gv Ts'BCt!LQ#JxݴyJ] C:= ċ(tRQ;^e1/-/A_Y)^6(p[_&N}njzb\->;nVb*.7p]M|MMM# ud9c47=iV7̪~㦓ødfÕ 5j z'^9J{rJЃ3Ax| FU9…i3Q/B)LʾRPx)04N O'> agYeHj*kblC=hPW!alfpX OAXl:XVZbr Zy4Sw3?WӊhPxzSq]y c:#   PpLj!!"#v##F$$$C)n+r, --...\56f7?e;"$%&')*-036:<>@ABCDEGHIKMPRTVXZ\^_`dilnptwy~ @20>@ !!""X##($X$$',,,-J-p---,../n5566<7@9Br;#(+,./1245789;=?FJLNOQSUWY[]abcefghjkmoqrsuvxz{+; /?GWhtz,8>CS^n"(5EUe % + u  + j   % ) 9  htz|   ,28DJLX^`lrt#<1LX^t".4`**+5r666717888M9w99c:XXG$G$FFG$G$FFFFFFFFFG$G$FG$G$FFG$G$G$G$FG$G$G$G$G$XFG$FFFFFFFFFFFFFFFFFXXFFFFFFFXXXXX!@ @H 0(  0(  B S  ?%Text1Text2Kontrollkstchen1Kontrollkstchen2Text3Text4Text5Text6Text7Text8Text9Text36Text10Text11Text14Text15Text20Text22Text12Text16Text18Text21Text23Text13Text17Text19Text24Text25Text27Text28Text29Text30Text32Text34Text35 _Ref57713817 _Ref57713971 /Gi-i} !9MauMu#0%+d:  !"#$@X{?{ 3K_s_5C% +d:999999999a:d:U[GR999999999a:d:33336~ !h},ACruz h58IpGLat"7k&$6$&,'*++!+..999999999a:d:0>IIL_t"5....V/V/W/W/W1W1X1X1333344444747575788889999999999S:]:`:`:d:ȟ a|v}$4~=^BN}B²TRE.|Ďh;8 DI+PrHFu^V ^`OJQJo( 8^8`OJQJo( ^`OJ QJ o(o  p^ `OJ QJ o(  @ ^ `OJ QJ o( x^x`OJQJo( H^H`OJ QJ o(o ^`OJ QJ o( ^`OJ QJ o(^`.^`.^`.^`. ^`OJQJo( ^`OJQJo( ^`OJQJo( ^`OJQJo(hh^h`. hh^h`OJQJo(^`OJQJo(hH^`OJ QJ ^J o(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHoP^P`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHoP^P`OJ QJ o(hH ^`hH. ^`hH. pp^p`hH. @ @ ^@ `hH. ^`hH. ^`hH. ^`hH. ^`hH. PP^P`hH. ^`hH. ^`hH. pp^p`hH. @ @ ^@ `hH. ^`hH. ^`hH. ^`hH. ^`hH. PP^P`hH.~}|u^V u^VrHFh;8 DI+ Pa2qVXrqW ^,1                  >On&_**V<+s/n=W-A RUKBE[[`bgeWRg,ah0tz5}VHf~}^) y Lh IL eX[`&}osEqIl7' S 6% *."/~1(3#f5?9'M9=7?D#@AW@ AWsAxQBFXL/SR]S4T3W_W[yWIY\aZ1g]*_i"kek'l^n?n^o pW qn tivy2{3f~u6?RGznr~'8.JbzCUh?|6<p1Z~VVWX?AwI,9/,]jjshb?S\ k#,!EwDbyZL~_Tve:>nH=o!L - f&^5R99@YYYY           (+c:0@0 0000000@000 0"0$0L@0,0.0`@04060p@0@Unknown G.[x Times New Roman5Symbol3. .[x Arial7..{$ CalibriC (PMingLiUe0}fԚ7$BCambria3.[x Times5. .[`)TahomaC.,.{$ Calibri Light?= .Cx Courier New;WingdingsA$BCambria Math h['['['0h0h!24q9q9  K#q?9n! xx&/ <Vorname> <Nachname> Ben Pankhurstvanda wallace jonesH          Oh+'0 $ D P \ ht| Ben Pankhurst Normal.dotmvanda wallace jones2Microsoft Office Word@G@d%M@p@p0 ՜.+,D՜.+,< hp  Woodscannon SARLhq9   TitleTitel 8@ _PID_HLINKSA@<lmailto:privacy@wada-ama.org0mailto:antidoping@fisski.comc{\https://adams-help.wada-ama.org/hc/en-us/categories/360001964873-ADAMS-Privacy-and-Security3:khttps://adams-help.wada-ama.org/hc/en-us/articles/360010175840-How-is-your-information-protected-in-ADAMS-KfThttps://adams-help.wada-ama.org/hc/en-us/articles/360012071820-ADAMS-Privacy-Policy'h_01121492-b374-476b-b44a-948d88fa3544KfThttps://adams-help.wada-ama.org/hc/en-us/articles/360012071820-ADAMS-Privacy-Policy'h_01121492-b374-476b-b44a-948d88fa3544O@https://www.wada-ama.org/kUMhttps://www.wada-ama.org/sites/default/files/resources/files/2021list_en.pdf0mailto:antidoping@fisski.com0mailto:antidoping@fisski.com  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry Fp Data 01TableKWordDocument 0SummaryInformation(DocumentSummaryInformation8MsoDataStore05 P 5IOIGURV13LQ==205 P Item  PropertiesUMacrosP P VBA P P   !"#$%'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTVWXYZ[^ 0* pHdProjectQ(@= l  V J< rstdole>stdoleP h%^*\G{00020430-C 0046}#2.0#0#C:\Windows\SysWOW64\e2.tlb#OLE Automation`ENormalENCrmaQF  * \C V!OfficgOficg!G{2DF8D04C-5BFA-101@B-BDE5gAjAe42ggram Files (x86)\@Common \Microsoft Shared\OFFICE1dir ThisDocument _VBA_PROJECT& PROJECT U4\MSO.DL L#P 14.0 Ob Li`brary'zMSF@Cs>MSFDHs3@eD452EE1-E08F1A-8-02608C4 D0BB4eFMl20L'B @r&/;"1ă} Ã00}#0ƒ# 50 ACEB6E1C5-39E7-4C2B-A034-2E648AE219DE6Users\fussek\AppData\Local\Temp\Word8.0c8.exdd=".E .`M BThisDocument(GTisDlcuen 2` H1zZ",^T""+^xME (S"SS"<(1Normal.ThisDocument8(%xAttribute VB_Name = "ThisDocument" Bas1Normal.VGlobal!SpaclFalse CreatablPre declaIdTru BExposeTemplateDeriv$Custom izC1a *\G{000204EF-0000-0000-C000-000000000046}#4.1#9#C:\PROGRA~2\COMMON~1\MICROS~1\VBA\VBA7\VBE7.DLL#Visual Basic For Applications*\G{00020905-0000-0000-C000-000000000046}#8.5#0#C:\Program Files (x86)\Microsoft Office\Office14\MSWORD.OLB#Microsoft Word 14.0 Object Library*\G{00020430-0000-0000-C000-000000000046}#2.0#0#C:\Windows\SysWOW64\stdole2.tlb#OLE Automation*\CNormal*\CNormalV4*\G{2DF8D04C-5BFA-101B-BDE5-00AA0044DE52}#2.5#0#C:\Program Files (x86)\Common Files\Microsoft Shared\OFFICE14\MSO.DLL#Microsoft Office 14.0 Object Library*\G{0D452EE1-E08F-101A-852E-02608C4D0BB4}#2.0#0#C:\Windows\SysWOW64\FM20.DLL#Microsoft Forms 2.0 Object Library*\G{CEB6E1C5-39E7-4C2B-A034-2E648AE219DE}#2.0#0#C:\Users\fussek\AppData\Local\Temp\Word8.0\MSForms.exd#Microsoft Forms 2.0 Object Library.E .`M   VThisDocument0:56bef30dThisDocument^ {cHU`|'WordkVBAWin16~Win32Win64xMacVBA6#VBA7#Project1 stdole`Project- ThisDocument< _EvaluateNormalOfficeuDocumentjMSFormsC HTMLCheckbox1 HTMLCheckbox2 HTMLCheckbox3 HTMLCheckbox4`"$ (ID="{D4F1AD33-DA57-4CCB-AB81-3D5DC6116560}" Document=ThisDocument/&H00000000 Name="Project" HelpContextID="0" VersionCompatible32="393222000" CMG="A4A65F05A7ADABADABADABADAB" DPB="484AB344B444B444" GC="ECEE174D1FF020F0200F" [Host Extender Info] &H00000001={3832D640-CF90-11CF-8E43-00A0C911005A};VBE;&H00000000 &H00000002={000209F2-0000-0000-C000-000000000046};Word8.0;&H00000000 ThisDocumentThisDocument  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89qPROJECTwm\)CompObj]r